8-K: Mountain Crest Acquisition Corp. V Announces Non-Binding Term Sheet for Business Combination with CUBEBIO

Mountain Crest Acquisition Corp. V has entered into a non-binding term sheet with CUBEBIO for a proposed business combination that would see CUBEBIO become a public company listed on the Nasdaq.

Summary

• Mountain Crest Acquisition Corp. V, a special purpose acquisition company (SPAC), has announced a non-binding term sheet with CUBEBIO Co., Ltd., a South Korean in-vitro diagnostics company.
• The proposed business combination would result in CUBEBIO becoming a publicly listed company on the Nasdaq.
• The pre-transaction equity value of CUBEBIO is estimated at $620 million, subject to adjustments based on due diligence and market conditions.
• CUBEBIO has developed technology for early cancer detection using urine analysis and holds 37 patents related to cancer diagnosis.
• CUBEBIO has secured a contract worth approximately $14.5 million with Taiwan Biotech Co., Ltd. for exclusive supply of cancer screening products in Taiwan, Vietnam, and Malaysia.
• Additional contracts with the United States and Japan are in the pipeline.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the potential for growth and the innovative technology, but tempered by the non-binding nature of the agreement and the inherent risks of SPAC mergers.

Positives

• CUBEBIO's innovative cancer detection technology has significant growth potential.
• The company has secured a substantial contract in Asia and has additional contracts in the pipeline.
• The proposed business combination will allow CUBEBIO to become a publicly traded company on the Nasdaq.
• Mountain Crest V has a track record of successfully completing four prior SPAC business combinations.

Negatives

• The term sheet is non-binding, and the deal is subject to due diligence and market conditions.
• The business combination is subject to various risks and uncertainties, including regulatory approvals and shareholder approval.
• The pre-transaction equity value of $620 million is subject to adjustment.

Risks

• The execution of a definitive merger agreement is not guaranteed.
• Legal proceedings could be initiated against Mountain Crest V and CUBEBIO.
• The business combination may not be completed due to failure to obtain necessary approvals or satisfy closing conditions.
• The COVID-19 pandemic could impact CUBEBIO's business and the ability to complete the transaction.
• There is a risk that the post-combination entity's securities may not be listed on Nasdaq.
• Changes in laws or regulations could adversely affect the business combination.
• Economic, business, and competitive factors could negatively impact Mountain Crest V or CUBEBIO.
• There are risks related to CUBEBIO's organic and inorganic growth and the timing of business milestones.

Future Outlook

The companies intend to execute a definitive merger agreement and complete the business combination, with CUBEBIO aiming to grow into a global company.

Management Comments

• Dr. Suying Liu, Chairman, CEO and CFO of Mountain Crest V, stated that CUBEBIO's technology and commercialization point to significant growth potential.
• Eun-jong Choi, CEO of CUBEBIO, expressed the expectation to execute a definitive merger agreement and grow CUBEBIO into a global company.

Industry Context

This announcement reflects the ongoing trend of SPACs seeking merger targets in the healthcare and biotechnology sectors, particularly companies with innovative diagnostic technologies. The focus on early cancer detection aligns with a growing global need for accessible and effective screening methods.

Comparison to Industry Standards

• The $620 million pre-transaction equity value is within the range of valuations seen in recent SPAC mergers in the biotech sector, although specific comparables would depend on CUBEBIO's revenue, profitability, and growth prospects.
• Other companies in the cancer diagnostics space, such as Exact Sciences and Guardant Health, have achieved significant market capitalizations, but they have different technologies and market positions.
• The $14.5 million contract with Taiwan Biotech is a positive sign of commercial traction, but it is relatively small compared to the revenue of established players in the diagnostics industry.

Stakeholder Impact

• Shareholders of Mountain Crest V will have the opportunity to vote on the proposed business combination.
• If the merger is successful, CUBEBIO will become a publicly traded company, potentially increasing its access to capital.
• Employees of CUBEBIO may benefit from the company's growth and increased visibility.
• Customers of CUBEBIO may benefit from the company's expanded reach and product development.

Next Steps

• The companies intend to execute a definitive merger agreement.
• They will file relevant materials with the SEC, including a proxy statement/registration statement on Form F-4.
• Mountain Crest V will mail the definitive proxy statement to its stockholders for a vote on the business combination.

Key Dates

Keywords

SPAC, Business Combination, CUBEBIO, Mountain Crest Acquisition Corp. V, Cancer Detection, In-Vitro Diagnostics, Nasdaq, Merger, Term Sheet